Table 3.
Item | MCT1 | MCT4 | Reference |
---|---|---|---|
Main substrate | Lactate, pyruvate, butyrate, acetoacetate, β-hydroxybutyrate, XP13512, GHB | Lactate, pyruvate, acetoacetate, β-hydroxybutyrate | Halestrap et al.45 Pierre and Pellerin46 |
Tissue expression | Kidney, stomach, intestine, liver, heart, skeletal muscle, prostate, testis, eye, lung, placenta, blood and brain | Skeletal muscle, kidney, liver, brain, stomach, testis, eye, leukocytes, placenta, lung, heart, blood, chondrocytes | Halestrap et al.45 Pierre and Pellerin46 Pellerin et al.47 |
Targeting drugs/inhibitors | - AZD3965 (Cayman Chemical Company) - 7ACC2 (Cayman Chemical Company) - Syrosingopine (INDOFINE Chemical Company, Inc.) | Syrosingopine | Curtis et al.48 Halford et al.49 Corbetet et al.50 Benjamin et al.51 |
Clinical relevance of aberrant expression | - Multiple cancers (colon, breast, prostate, pancreas, glioblastoma, cervix) - EIHI, IBD, ketoacidosis | - Multiple cancers (colon, breast, prostate, pancreas, ccRCC) - Obesity, RA | Thibault et al.52 Tosur et al.53 Balasubramaniam et al.54 Fisel et al.55 |
ccRCC, clear cell renal cell carcinoma; EIHI, exercise induced hyperinsulinism; IBD, inflammatory bowel disease; RA, rheumatoid arthritis.